The role of lncRNA-mediated pyroptosis in cardiovascular diseases

Cardiovascular disease (CVD) is the leading cause of death worldwide. Pyroptosis is a unique kind of programmed cell death that varies from apoptosis and necrosis morphologically, mechanistically, and pathophysiologically. Long non-coding RNAs (LncRNAs) are thought to be promising biomarkers and therapeutic targets for the diagnosis and treatment of a variety of diseases, including cardiovascular disease. Recent research has demonstrated that lncRNA-mediated pyroptosis has significance in CVD and that pyroptosis-related lncRNAs may be potential targets for the prevention and treatment of specific CVDs such as diabetic cardiomyopathy (DCM), atherosclerosis (AS), and myocardial infarction (MI). In this paper, we collected previous research on lncRNA-mediated pyroptosis and investigated its pathophysiological significance in several cardiovascular illnesses. Interestingly, certain cardiovascular disease models and therapeutic medications are also under the control of lncRNa-mediated pyroptosis regulation, which may aid in the identification of new diagnostic and therapy targets. The discovery of pyroptosis-related lncRNAs is critical for understanding the etiology of CVD and may lead to novel targets and strategies for prevention and therapy.

1. Introduction

In recent decades, the development of pyroptosis has brought a fresh notion for the pathophysiology of cardiovascular illnesses (1). Pyroptosis-related proteins gasdermins (GSDMs) generate porous membrane channels, and cell membrane rupture results in the release of inflammatory factors and more severe inflammatory responses (2–5). Long non-coding RNAs (LncRNAs) (6) are non-coding RNA molecules that contain more than 200 nucleotides in eukaryotes. These non-coding RNAs serve a variety of biological roles, including molecular scaffolding in the nucleus, variable splicing assistance, chromosomal shape regulation, translation regulation, and promoting or inhibiting messenger RNA (mRNA) breakdown in the cytoplasm (7). Several investigations have found that lncRNA-mediated pyroptosis is linked to the onset and progression of CVD (8, 9). However, the precise involvement of lncRNA-mediated pyroptosis in CVD is unknown. The function of lncRNA-mediated pyroptosis in CVD is discussed in this research (Table 1).

TABLE 1

Table 1. LncRNAs-mediated pyroptosis with characterized functions in cardiac diseases.

2. Overview of pyroptosis

Pyroptosis, also known as inflammatory cell necrosis, is characterized by the body's programmed recognition of intracellular pathogens and defence, resulting in constant cell expansion until the cell membrane bursts, followed by the release of intracellular contents and pro-inflammatory mediators into the cell's exterior to activate a robust inflammatory response (2). Pyroptosis is a type of programmed cell death that occurs quicker than apoptosis and regulated by inflammatory protease activity. Inflammatory proteases are the caspases (cysteine-dependent aspartic specific proteases) family members. From the inception of the word “pyroptosis” to the finding of the caspase protein family implicated in pyroptosis inflammation, representing a significant advance in cell death research has been a long road.

Friedlander was the first to reveal that Anthrax lethal toxin (LT) may trigger cell death and fast release of cell contents in primary mouse macrophages in 1986 (24). Two related discoveries in 1989 and 1996 respecteively showed that inflammatory medium, interleukin-1-converting enzyme (ICE) could convert precursor IL-1 to adult IL-1 (25–27), and that invasive plasmid antigen B (ipaB) of Shigella flexion could directly bind to ICE and activate ICE enzymes in infected macrophages (28). This type of cell death was initially thought to be apoptosis because some of its features, such as caspase dependence, DNA damage, and nuclear aggregation, were similar to apoptosis. However, subsequent studies have found that this form of death is distinct from apoptosis - in 2001 proposed the term sclerosis to describe proinflammatory programmed cell death, which distinguishes between pyroptosis and apoptosis (a non-inflammatory program of cell death) (29). It was first suggested that inflammasomes could activate inflammatory cysteine proteases and process IL-1β in 2002 (30). As studies progressed, it was found that atypical caspase-11 could also induce cell death in host infection with Salmonella independent of caspase-1 (31). During pyroptosis, the N-terminal domain of cleaved Gasdermin D (GSDMD) can oligomerize in the cell membrane to form pores and induce cell membrane rupture (2, 3). This GSDMD pore formation is thought to be a critical factor in the early onset of pyroptosis, causing plasma membrane rupture and cell swelling.

3. Gasdermin and the mechanism of pyroptosis

The GSDM family (32) contains six members, GSDMA, GSDMB, GSDMC, GSDMD, GSDME and DFNB59 (33), of which GSDMD and DFNB59 have received the most attention in the study of pyroptosis (34). GSDMD was considered as an executor of pyroptosis for the first time in 2015 (32). The N-terminal structural domains of all members of this family function to induce cellular pyroptosis-except for DFNB59. All GSDM members, such as GSDMD, consist of two conserved structural domains, amino-terminal and carboxy-terminal, linked by an intermediate flexible amino acid linker that contains the enzymatic cleavage site for highly conserved caspases. Its amino-terminal (N-terminal) structural domain has a molecular weight of 30 kDa can form a Gasdermin pore (35, 36), also known as a Pores-forming domain (PFD), while the carboxy-terminal (C-terminal) structural domain with a controlled molecular weight size of 20 kDa is also known as a Repressor domain (RD). RD can be involved in the control of PFD activity, both structural fields are involved in the induction of pyroptosis. The RD can be applied in possession of PFD activity, and both structural domains are interested in installing pyroptosis (37). When the amino acid linker between the two structural domains is cleaved, the RD is separated from the PFD (38). The released PFD is integrated into the cell membrane, where large aggregates of PFD monomers form 10∼15 nm diameter pores (39–41) (Figure 1). The essence of cell pyroptosis occurs due to the appearance of GSDMD pores on the cell membrane surface, causing a leaky plasma membrane to erupt into an inflammatory response. The open GSDMD pores break the normal permeability barrier of the plasma membrane. In terms of ion homeostasis, the presence of the cleavage pore allows the balance of the concentration gradient inside and outside the cell to be disrupted, resulting in sodium ions being drawn into the cell by the force of the concentration gradient and the electrical gradient, the most immediate damage when sodium ions flow into the cytoplasm is the entry of large amounts of water into the cytoplasm, resulting in an increase in cell volume; in terms of inflammatory factors, the pyroptosis process consists of the cleavage of IL-1β and IL-18 by Caspase-1, before the membrane The mature cytokines are produced before rupture and are present in the cytoplasm as cytoplasmic restriction proteins. The 10∼15 nm diameter gastrin pore is much larger than IL-1β (4.5 nm) and IL-18 (5.0 nm) (39) after pyroptosis activation to produce lytic pores, releasing them from cells before they are lysed, triggering the severe inflammatory response.

FIGURE 1

Figure 1. Molecular mechanism of pyroptosis. (The activation of pyroptosis can be divided into classical caspase-1 dependent pathways and non-classical caspase-1 independent pathways. The precursor caspase-1 protein complex is activated after recognizing the pathogen's stimulus signal. Activated caspase-1, cleaved GSDMD to form peptides containing the active domain of the nitrogen end of GSDMD, induced cell membrane perforation, cell rupture, release of contents, and cause inflammation; meanwhile, activated caspase-1 cleaves the precursors of IL-1β and IL-18 to form active IL-1β and IL-18, which are released into the extracellular space to recruit inflammatory cells to gather and amplify the inflammatory response. Bacterial lipopolysaccharides (LPS) bind to human caspase-4/5 and mouse caspase-11, mediating inflammation and causing cell necrosis. On the one hand, caspase-4/5 and 11 can be activated in response to the stimulation of LPS and other signals, the activated caspase-4/5 and 11 can cleave GSDMD and form peptides containing the active domain of the nitrogen end of GSDMD; On the other hand, they induce the activation of caspase-1, which cleaves the precursors of IL-1β and IL-18 to form active IL-1β and IL-18 and releases them outside the cell, recruiting inflammatory cells to gather and amplifying the inflammatory response.).

Nowadays, research on the molecular mechanisms that induce cell death by pyroptosis has focused on the caspase-1-dependent classical pathway and the caspase-1-independent non-classical pathway (42).

3.1. Caspase-1-dependent classical pathway

As mentioned earlier, upon recognition of stimulatory signals from pathogens such as bacteria and viruses, the intracellular pattern expression receptors activate the inflammatory vesicle junction protein caspase recruitment domain (ASC) to bind with pro-caspase-1 protein forming a protein complex (43) and facilitates the activation of caspase-1 (44, 45). The activated caspase-1, cleaves GSDMD to form a peptide containing the nitrogen-terminal active domain of GSDMD and induces cell membrane perforation and cell rupture, releasing the contents and causes an inflammatory response.The activated caspase-1 can also cleave the precursors of IL-1β and IL-18 to form active IL-1β and IL-18, which are released into the extracellular space and recruit inflammatory cells to aggregate and amplify the inflammatory response (46, 47).

3.2. Caspase-1-independent non-classical pathway

In contrast to the classical pathway, human caspase-4/5 and mouse caspase-11 can bind to bacterial lipopolysaccharides (LPS), mediating inflammation and leading to cellular necrosis (48, 49). Caspase-4/5 and 11 can also be activated in response to stimulation by signals such as bacteria. Activated caspase-4/5 and 11 cleave GSDMD and form peptides containing the nitrogen-terminal active domain of GSDMD (50, 51). GSDMD induce cell membrane perforation, cell rupture and release of contents, causing an inflammatory response. GSDMD induces activation of caspase-1and cleaves the precursors of IL-1β and IL-18, forming active IL-1β and IL-18, and releasing them extracellularly to recruit inflammatory cells to aggregate and amplify the inflammatory response. In addition, activated caspase-11 can induce cellular inflammatory reactions by inducing membrane pore formation in GSDMD cells and promoting K + efflux through the Pannexin-1/ATP/P2X7 pathway, mediating NLRP3/ASC/caspase-1 activation and promoting IL-1β maturation and release. Both of these activation pathways can cleave GSDMD to induce the formation of cell membrane gaps and also stimulate the activation of IL-1β and IL-18 to promote a more intense extracellular inflammatory response.

Another caspase-3-dependent pyroptosis pathway differing from caspase-1/4/5/11 has recently been identified, which induces GSDMD-dependent pyroptosis, in that caspase-3 induces cell pore formation by cleaving GSDME and promoting the recruitment of the GSDME-N structural domain to the cell membrane, leading to pyroptosis (39). The distribution and expression level of GSDME determines how caspase-3 activates cell death. When cells overexpress GSDME, activated caspase-3 induces cell pyroptosis, whereas, for cells with low GSDME expression, caspase-3 induces apoptosis after activation of caspase-3 induces apoptosis. This caspase-3-dependent mode of cell death is known as apoptosis-like pyroptosis (52).

To some extent, pyroptosis is a double-edged sword. On the one hand, moderate pyroptosis contributes to cellular homeostasis and can effectively prevent excessive cell proliferation, thereby protecting the host (53).On the other hand, high levels of pyroptosis can lead to inflammation, which is detrimental to the maintenance of homeostasis in vivo. There is growing evidence that pyroptosis may be an effective anti-microbial defence mechanism in the host during infection. Pyroptosis eliminates pathogenic bacteria by lysing infected cells and exposing pathogens to extracellular defences, such as by telling pathogens to neutrophils with solid anti-microbial activity. In addition, pyroptosis facilitates pathogen clearance by sensing an alarm signal from immune cells recruited to the site of infection. During pyroptosis, IL-1β (54) and IL-18 are released extracellularly as cell integrity is disrupted, promoting leukocyte infiltration and activation. The release of inflammatory mediators by cell lysis, including factors such as ATP (55), IL-1 and heat shock proteins, stimulates the production of pro-inflammatory cytokines by activating pattern recognition receptors, which contribute to the control and eventual resolution of microbial infections and their return to a homeostatic state (2, 56).

However, mutations in intracytoplasmic receptors [NOD-like receptors (NLR)] or the persistence of sterile inflammatory stimuli can lead to excessive pyroptosis (2), which can be detrimental to the host and, if left unchecked, can lead to disease (57, 58). Excessively pyroptosis cells increase the inflammatory mediators IL-1β, IL-18 and the alarm protein HMGB-1. HMGB-1 has been reported to cause severe sepsis and infectious shock (59). This can harm the host and, if left unchecked, can lead to disease.

4. The role of pyroptosis in cardiovascular disease

Pyroptosis causes structural changes in the cardiovascular system that result from pyroptosis-mediated pathological changes in vascular endothelial cells, vascular smooth muscle cells, monocytes and macrophages, such as injury, proliferation and fibrosis. For example, oxidized low-density lipoprotein (Ox-LDL)-induced endothelial cell pyroptosis can cause abnormal endothelial proliferation and vascular stenosis; oxidative stress (60), NLRP3 inflammatory vesicles and lncRNA-mediated pyroptosis can contribute to the formation of myocardial fibrosis (61); IL-1β and IL-18-mediated pyroptosis responses directly lead to myocardial hypertrophy, ventricular hypertrophy and myocardial ischemia and hypoxia in diabetic patients (62). The above-mentioned cellular activation by pyroptosis signalling pathways leads to the formation of myocardial fibrosis. The above-mentioned CVD caused by the activation of cell death by the pyroptosis signalling pathway are of increasing interest. Uncovering risk factors for the development of cell death in the pyroptosis pathway is of paramount importance.

The pyroptosis-regulated cell death is mainly regulated by various caspase-selective pathways, including caspase-1, in response to pathogenic and bacterial signalling stimuli, ultimately leading to the formation of GSDMD pore and the release of mature IL-1β, IL-18 and other inflammatory factors. This pathogen-activated pathway releases inflammatory factors and inflammatory bursts regulated by the expression of these proteins mediated by the transcriptional and translational involvement of miRNAs in their pathway networks (63). Long-stranded non-coding RNAs (LncRNAs), precursor molecules for small molecule RNAs (64), including miRNAs, have been shown to regulate the expression of downstream genes by interfering with the shearing of miRNAs. Here we focus on the role of lncRNA-mediated pyroptosis in the cardiovascular system.

5. Mechanism of lncRNA-mediated pyroptosis in causing cardiovascular diseases

Only <2% of the human genome is transcribed into protein-coding RNAs, and many RNA transcripts with limited or no protein-coding capacity are known as non-coding RNAs (65). LncRNAs are non-coding RNA molecules of more than 200 nucleotides in eukaryotes. In the regulation of transcription, lncRNAs can directly regulate transcription by forming R-loop structures to aggregate transcription factors or by interfering with Pol II transcription at target motifs, and can affect mRNA conversion in a variety of ways (66). In tissue and embryo development, lncRNAs are involved in the regulation of genomic imprinting, multipotential differentiation of stem cells, embryonic development, cardiac development, haematopoiesis and immune system, so measuring the expression of lncrnas in different partitions or disease states can help to understand their function, reveal their mechanism of action, or identify useful molecular markers (67). Based on the location on the genome, lncRNAs can be classified into sense lncRNAs, antisense lncRNAs, enhancer lncRNAs, intergenic lncRNAs, bidirectional lncRNAs and intronic lncRNAs based on their location concerning their neighbouring genes (68).

In recent years, various lncRNAs have regulated cardiac development and disease pathogenesis by mediating pyroptosis (68). LncRNAs located in the nucleus and regulate gene expression at the epigenetic level. In contrast, a small number of lncRNAs (15%) are present in the cytoplasm and are involved in regulating the translation process. In the nucleus, lncRNAs play a structural role in forming and maintaining subnuclear structural domains, together with various nuclear proteins. For example, lncRNA NEAT1 plays a crucial role in creating paraspeckles (a type of atomic body). Quinozod proposes a model in which lncRNAs establish nuclear structural domains with target genes and bind to proteins to form RNA-DNA-protein complexes. In brief, lncRNAs recruit proteins to modify chromatin, triggering conformational changes leading to transcriptional regulation. The model currently applies to all lncRNAs and is implemented through four different mechanisms:

Signalling lncRNAs (69) can respond to a variety of stimuli and thus precisely regulate gene expression, for example, the voltage-gated potassium channel subfamily KQT membrane 1 justice/antisense transcript 1 (kcnq1ot1) recruits histone methyltransferases (e.g., multicomb repressor replicon PRC2) to specific sites of action in chromatin and suppresses abnormal focal activity in cardiomyocytes by triggering chromatin methylation-induced transcriptional silencing (70). The molecular decoy lncRNA inhibits transcription in a manner that isolates regulatory factors, and several lncRNAs are known to have decoy mechanisms of action involved in pyroptosis-mediated cardiovascular diseases, such as myocardial infarct-associated transcription factors (MIAT) involved in selective shearing processes and anti-myocardial hypertrophy Heavy-stranded RNA transcript (MHRT) and lncRNA lung adenocarcinoma transcript 1 (MALAT1) have been reported to be involved in the regulation of endothelial cell function and vascular growth in the cardiovascular system (71). Guided lncRNAs (69, 71) are involved in the regulation of endothelial cell function and vascular growth by binding to ribonucleoproteins and directing them to specific targets, for example FENDRR can form a complex with PRC2 to silence the expression of target genes, or with TrxG/Mll proteins to activate gene expression; scaffold lncRNAs direct regulation in complexes with multiple transcriptional activators or repressors. CDKN2B-AS1 (also known as ANRIL) binds PRC1 and PRC2 to regulate chromatin methylation, leading to silencing of the INK4b-ARF- ANRIL has been identified as a genetic risk factor for coronary artery disease, and its expression levels correlate with left ventricular dysfunction after myocardial infarction (69, 72).

LncRNAs play a variety of roles in biological processes due to their different structures and mechanisms of action. Recent developmental experimental studies on lncRNAs have confirmed multiple mechanisms of regulating the process of cardiovascular diseases by mediating pyroptosis, including many complex diseases such as diabetic cardiomyopathy, atherosclerosis, myocardial infarction and other cardiovascular system diseases. The research focuses on exploring the mechanism of lncRNAs as a precursor of miRNA to interfere with the occurrence of pyroptosis of cardiomyocytes, the formation of fibrosis and lipid accumulation in the intima of blood vessels. These recent studies have greatly updated the existing understanding of lncRNA-pyroptosis-cardiovascular diseases, which can provide great help for clinical development to diagnose and treat cardiovascular diseases by utilizing the occurrence of pyroptosis. The mechanisms of lncRNA's effects on diabetic cardiomyopathy, atherosclerosis, myocardial infarction and other cardiovascular system diseases by mediating pyroptosis are summarized in Figure 2 and Table 1.

FIGURE 2

Figure 2. LncRNAs-mediated pyroptosis in cardiac development and diseases. (LncRNA-mediated pyroptosis regulates cardiovascular diseases through multiple mechanisms. The color of each lncRNA in the figure is the same as that corresponding to the color that guides the changes in the course of cardiovascular disease caused by miRNA-mediated pyroptosis. Diabetic cardiomyopathy was orange: the downregulation of TINCR, MIAT, and Kcnq1ot1 jointly promoted the expression of miR-214-3p, preventing pyroptosis-mediated myocardial fibrosis and enhancing myocardial systolic function. Atherosclerosis is bluish-purple: The overexpression of GAS5 inhibits miR-34b-3p, up-regulates miR-29b-3p, down-regulates HCG11 promoting the expression of miR-224-3p, H19 can directly act on pyroptosis, interfering with the activation of NF-κB by ox-LDL and reducing the release of inflammatory factor NLRP3. Myocardial infarction is turquoise and pink: KLF3-AS1 promoted the expression of miR-138-5p, FAF inhibited the expression of miR-185-5p, NEAT1 regulated the transformation of m6A, TUG1 inhibited the expression of miR-186-5p, and downregulation of SOX2OT promoted the binding of miR-23b and TLR4/30UTR. Thus, the myocardial infarction mediated by pyroptosis was improved and the myocardial cell injury induced by LPS was alleviated. The specific mechanism of lncRNA is shown in the figure.).

5.1. Diabetic cardiomyopathy

Diabetic cardiomyopathy (DCM) is a disease featured witn substantial cardiac lesion characterised by myocardial fibrosis and cardiac hypertrophy caused by chronic diabetes mellitus that occurs in the absence of hypertensive heart disease, coronary artery disease and heart valve disease (73). Several studies have shown that DCM is partially associated with pyroptosis, the most classic being myocardial fibrosis mediated by caspase-1 activation in a high-glucose environment: the lncRNA Kcnq1ot1, a signalling lncRNA, is highly expressed in the left ventricular tissue of diabetic mice, and a recent study by Fan Yang et al. showed that knockdown of Kcnq1ot1 by small interfering RNA reduced the expression of caspase-1 (10). The levels of NLRP3, caspase-1, IL-1β and GSDMD-N were significantly increased in the cardiac tissues of diabetic mice. However, their levels were significantly reduced by immunohistochemical analysis after kcnq1ot1 silencing (74). NLRP3, caspase-1 and IL-1β mRNA and protein expression levels were significantly elevated in diabetic (DM) mice and were reversed after kcnq1ot1-shRNA treatment. In addition, GSDMD-N protein expression levels were significantly elevated in diabetic mice and reversed after kcnq10t1 inhibition, and these effects were achieved through a complementary regulatory relationship between kcnq10t1 and miR-214-3p, caspase-1 and miR-214-3p (10). At the tissue level, kcnq1ot1 regulates caspase-1 expression in cardiac fibroblasts via miR-214-3p and thereby reduces irreversible myocardial fibrosis due to myocyte pyroptosis, as evidenced by the elevation induced by kcnq1ot1 silencing, leading to significant inhibition of miR-214-3p-targeted caspase-1 and its downstream inflammatory cytokine IL-1β is significantly inhibited (75). Previous studies have shown that IL-1β is closely associated with cardiac fibrosis and that prolonged exposure to IL-1β activates the TGF-β1 pathway, inducing the conversion of microvascular endothelial cells to myofibroblasts (76), leading to increased collagen synthesis, promotion of myocardial remodelling and increased interstitial myocardial fibrosis. lncRNA kcnq10t1 regulates pyroptosis in the diabetic heart possibly through kcnqot1/miR-214-3p/caspase-1/TGF-β1 pathway.

LncRNA Growth inhibitor-specific transcript (GAS5) has been reported to regulate various cardiac functions through pyroptosis (77), such as inhibition of cardiac hypertrophy, reduction of cardiac fibrosis and improvement of myocardial ischemia and hypoxia leading to cardiac dysfunction. Recent microarray analysis of lncRNA profiles in an in vitro DCM model (78) showed significant downregulation of GAS5 in cardiomyocytes. A study showed that GAS5 improved cardiac function and myocardial hypertrophy in DCM mice (15). GAS5, a competitive endogenous lncRNA, enhanced the aryl hydrocarbon receptor (AHR) expression by suppressing miR-34b-3p, thereby inhibiting NLRP3 inflammatory vesicle activation-mediated energy. miR-34b-3p upregulation in the DCM model significantly enhanced caspase-1 activity and levels of IL-1β and IL-18 in HL-1 cells, whereas GAS5 overexpression effectively abolished caspase-1 activity (79). LncRNA GAS5 regulates pyroptosis in the diabetic heart, possibly by targeting GAS5/miR-34b-3p/AHR to inhibit NLRP3 inflammatory vesicle activation in diabetic cardiomyopathy achieve.

In recent years, many lncRNAs have been reported to be involved in regulating diabetic cardiomyopathy by mediating pyroptosis. For example, MALAT1 expression is increased in the diabetic heart (80). Its knockdown improves cardiac contractile function and reduces inflammatory factors such as TNF-α, IL-6 and IL-1β in the diabetic myocardium, thus suggesting that MALAT1 may be involved in the inflammatory response to diabetic cardiomyopathy. Another study reported that MALAT1 upregulates inflammatory mediators TNF-α and IL-6 in high-glucose-treated endothelial cells by activating serum amyloid antigen. Large amounts of circulating lncRNA such as LIPCAR, SENCR and MIAT are valuable predictors of left ventricular diastolic function and remodelling in diabetic patients.

Many studies have revealed that several lncRNA, including MIAT and kcnq1ot1, are associated with DCM through inflammatory mechanisms. LncRNA myocardial infarction-associated transcript (MIAT) alleles, a lncRNA enriched in diabetic cardiomyocytes, act as competing endogenous RNAs (ceRNAs), forming a feedback loop with vascular endothelial growth factor. Furthermore, MIAT, CASP1 and IL-1b expression levels were upregulated and miR-214-3p expression levels were downregulated in serum of diabetic patients (81). In contrast, MIAT-silenced myocardial tissue of DM mice was associated with myocardial infarction compared to the regular group. Protein expression of caspase-1, IL-1b, IL-18, and GSDMD was significantly down-regulated and miR-214-3p expression was upregulated in MIAT-silenced myocardial tissue compared to the regular group, with the same results in both human and mouse genera (81, 82). Similarly, mRNA expression of caspase-1 and IL-1b was significantly reduced and miR-214-3p expression was elevated in mouse hearts following MIAT knockdown or caspase-1 inhibitor application, suggesting that MIAT may affect cellular pyroptosis in diabetic cardiomyopathy by targeting miR-214-3p to regulate the expression of caspase-1 and IL-1b process. It has been shown that MIAT is involved in both left ventricular diastolic function and myocardial remodelling in diabetic patients (83).

Pyroptosis-mediated inflammation in vascular endothelial cells and cardiomyocytes is essential in the late complications of cardiac dysfunction in diabetic patients. LncRNAs can regulate the development of diabetic cardiomyopathy by mediating the activation of pyroptosis-associated factors and affecting ventricular remodelling through multiple pathways that interfere with the integrity of cardiomyocytes and vascular endothelial cells, giving us many hints and motivation for research. The causal relationship and consequences of pyroptosis and chronic inflamation in cadiac myppathy are still to be further studied.

5.2. Atherosclerosis

CVD caused by atherosclerosis (AS) is the major cause of mortality in the global population (84). Pyroptosis as a form of inflammation-mediated cell death has become the focus of research to advance the pathological process of atherosclerosis (60, 85). Endothelial cell dysfunction is the earliest link in the development of atherosclerosis. Therefore, maintaining endothelial cells' integrity and normal function is essential to prevent and treat atherosclerosis (86).

Research on the role of lncRNAs in the pathology of atherosclerosis is still in its infancy. Several lncRNAs have been identified as being involved in the development of atherosclerosis (87). Atorvastatin is commonly used to control abnormal lipid metabolism in patients with atherosclerosis. Wu et al. demonstrated that atorvastatin can be expressed at both mRNA and protein levels by upregulating the expression of Nexilin F-actin binding protein antisense RNA1 (lncRNA NEXN-as1) and NEXN Reduction of NLRP3, caspase-1, GSDMD, IL-1β and IL-18 to inhibit pyroptosis (87). In RT-PCR analysis of samples from the clinic, RNA levels of NEXN and NEXN- as1 were lower in patients' atherosclerotic plaques than in healthy intimal tissue; their expression levels would be lower in advanced atherosclerotic plaque tissue. Recent study demonstrated that overexpression of NEXN-as1 inhibited NF-κB activity and downregulated endothelial cell adhesion molecules and inflammatory factors (87). These inhibitory effects of NEXN-as1 were abolished by knocking down NEXN: artificial knockdown of NEXN in Apoe knockout mice promoted atherogenesis, increased macrophage abundance in atherosclerotic lesions, and increased expression of adhesion molecules and inflammatory cytokines, whereas increased NEXN expression prevented atherosclerosis (88). In contrast, NEXN-as1 can protect against the progression of atherosclerosis by interacting with the chromatin remodeler BAZ1A and upregulating its homologous protein-encoding gene NEXN, thereby inhibiting endothelial cell activation and monocyte recruitment, ultimately providing protection against atherosclerosis progression (89). In addition, NEXN- as1 and NEXN may promote plaque stabilization by inhibiting adhesion molecules and extracellular matrix-degrading enzymes and reducing macrophage abundance and lipid content, hallmarks of vulnerable atherosclerotic plaques.

The expression of NLRP3 is increased in the aorta of patients with coronary artery disease, and its expression correlates with the severity of coronary artery disease (90). Various lncRNAs are involved in NLRP3 activation during pyroptosis, for example, lncRNA MALAT1 associated with NLRP, with low mustard acid reducing NLRP3 gene expression in macrophages by decreasing lncRNA MALAT1, and lncRNA MALAT1 promoting NLRP3 gene expression in myocardial ischemia-reperfusion injury (91–93).

In addition, recent studies suggest that the lncRNA-miRNA-mRNA regulatory network may play a vital role in the cellular pyroptosis process (8, 94). LncRNA MALAT1 may use this network to regulate NLRP3 expression by adsorbing endothelial cell miR-22 through a competitive inside-supporting RNA mechanism. By observing human umbilical vein endothelial cells transfected with miR-22 in a high glucose culture environment, the expression level of miR-22 decreased significantly after high glucose stimulation, while the level of lncRNA MALAT1 in endothelial cells changed in contrast to miR-22; overexpression of miR-22 could attenuate MALAT1's pyroptosis of endothelial cells induced by high glucose, suggesting that MALAT1/miR-22/NLRP3 regulatory pathway is involved in high-glucose-induced endothelial cell pyroptosis (95).

The involvement of the lncRNA-miRNA-mRNA regulatory network in mediating pyroptosis-induced endothelial cell damage and hence atherosclerosis applies to many existing studies: melatonin reduced ox-LDL-induced pyroptosis in human aortic endothelial cells by decreasing the lncRNA MEG3, and the possible molecular mechanism was that the adsorption of miR-223 by MEG3 unlocked the target gene NLRP3. Han et al. found (63) that low doses of erucic acid reduced the lncRNA MALAT1, thereby reducing macrophage pyroptosis in diabetic atherosclerotic rats, probably through the MALAT1/miR-23c/ELAYL1 pathway. LncRNAs may act as significant regulators of pyroptosis in atherosclerotic heart disease and are potential therapeutic targets, but further studies are needed to demonstrate their utility as biomarkers.

5.3. Myocardial infarction

Myocardial infarction (MI) is a severe coronary artery-related disease caused primarily by ruptured atherosclerosis or an imbalance in the supply and demand of oxygen to the heart muscle (96). When atherosclerosis ruptures, the released plaque collects platelets and causes occlusion of the coronary arteries, leading to ischaemic necrosis of the myocardium (97). Like atherosclerosis, pyroptosis is involved in cardiomyocyte injury by mediating the inflammatory response, and the pyroptosis pathway is also a potential therapeutic target for cardiovascular disease (98). It is considerable evidence that lncRNAs act as competing ceRNAs in myocardial infarction to regulate cellular biological activity in a manner that mediates the processes of the pyroptosis network.

Many recent bioinformatic predictions of the involvement of lncRNAs in mediating the pyroptosis pathway in regulating myocardial infarction have been confirmed (98). For example, the lncRNA KLF3-AS1/miR-138-5p/Sirt1 in exosomes from human mesenchymal stem cells (hMSCs) is involved in the protective effect on hypoxic cardiomyocytes (11). The myocardial infarction area was significantly reduced in rats with myocardial infarction injected with KLF3-AS1 exosome, and the expressions of NLRP3, caspase-1, GSDMD, IL-1β and IL-18 in KLF3-AS1-overexpressed myocardial infarction mice were also significantly decreased. The term of KLF3-AS1 and Sirt1 was upregulated after transfection with miR-138-5p inhibitor (99). Transfection with Sirt inhibitor reversed the protective effect of KLF3-AS1 on hypoxic cardiomyocytes, suggesting that lncRNA KLF3-AS1 acts as a competitive endogenous RNA by inhibiting miR-138-5p from regulating the expression of Sirt1 and thus inhibiting the activation of pyroptosis factor of the lncRNA KLF3-AS1, as a ceRNA, inhibits the activation of Sirt1 and thus protects cardiomyocytes (11, 100). Another study found that Sirt1 was downregulated in myocardial infarction and that Sirt1 overexpression effectively ameliorated myocardial injury caused by myocardial infarction. Data from vascular endothelial cells showed that Sirt1 inhibited the expression of NLRP3 and ASC in addition to the maturation of caspase-1 and the inflammatory cytokine IL-1β, suggesting that Sirt1 has an inhibitory effect on the activation of NLRP3 inflammatory vesicles and that Sirt1 has a protective effect on vascular endothelial cells.

Another bioinformatically predicted and validated pathway is the lncRNA FAF/miR-185-5p/PAK2 axis that mediates cardiomyocyte pyroptosis to ameliorate acute myocardial infarction. lncRNA FGF9 associated factor (FAF) is a recently identified pathway downregulated in infarcted myocardium and inhibits cardiomyocyte pyroptosis through transcriptional regulation of FGF9. Li et al. also demonstrated that the downregulation of miR-185-5p expression contributed to endothelial neovascularisation, which further reduced the decline in cardiac function in mice after infarction (101). Overexpression of the lncRNA FAF in the myocardium improved the pathological ultrastructural changes associated with acute myocardial infarction, such as myofilament lysis, loss of plasma membrane integrity, mitochondrial swelling and loss of cristae (102). Pathological changes. In addition, overexpression of myocardial lncRNA FAF in the rat myocardial ischemia/hypoxia model protected the membrane integrity of hypoxia/ischemia-induced focal cell death better than the control group. Recent report indicated that rat myocardial cells under hypoxia/ischemia induction showed significant cytosolic rounding, bubbles on the cell surface with bulging masses, and myocardial cells in the hypoxia and FAF overexpression group showed significantly reduced morphological differences (14). It has also been shown that modulation of miR-185-5p and PAK2 can exert cardioprotective effects. Furthermore, PAK2 expression was downregulated in hypoxic and ischemic cardiomyocytes. That overexpression of lncRNA FAF upregulated PAK2 protein levels under hypoxic conditions, reversed under transfected miR-185-5p co-culture conditions. Transfection with miR-185-5p inhibitor helped to reduce cellular pyroptosis, and in contrast, miR-185-5p mimicked the increased cellular pyroptosis under hypoxic ischemia. It is reasonable to believe that lncRNA FAF promotes the release of PAK2 by inhibiting the miR-185-5p pyroptosis pathway, which attenuates the cellular pyroptosis response and reduces the size of myocardial infarction.

In addition, pyroptosis-induced inferior coronary micro thrombosis is an essential pathogenesis of myocardial infarction. Coronary microemboli induce inflammatory responses and oxidative stress in the body in additiong to its blockage of blood stream. Microemboli leading to a collective burst of inflammatory reactions have recently been found to be mediated by various lncRNAs. LncRNA Sox2 overlapping transcripts (Sox2OT), a long-stranded non-coding RNA localized to the human chromosome 3q26.3 (Chr3q26.3) locus, a long-stranded non-coding RNA with an intron region containing the Sox2 gene, which is one of the primary regulators of pluripotency (13). Sox2OT was previously reported to enhance cardiac dysfunction by promoting re-releasing of reactive oxygen species (ROS) in mice with septic cardiomyopathy (103). Recently, the ability of Sox2OT to act as a competitive ceRNA in inducing various pyroptosis pathways has been increasingly demonstrated. In a recent survey, Xuan et al. concluded that silencing Sox2 downregulates NF-κB expression in cardiomyocytes, an effect that may be mediated by the miR-23b/TLR4/LPS pyroptosis pathway (13). Pyroptosis is a caspase-1-dependent form of programmed cell death inflammation. NF-κB upregulates pyroptosis-associated inflammasome NLRP3 levels, activates caspase-1 activity and promotes GSDMD expression, promoting the inflammatory response and inducing pyroptosis. In the rat infarct model, silencing of Sox2OT decreased NF-κb p65 phosphorylation and downregulated NLRP3, GSDMD and caspase-1 protein levels compared to the average infarct model, whereas overexpression of Sox2OT had the opposite result. RISC is a ribonucleoprotein complex containing proteins such as Argonaute (Ago) that binds mature miRNAs, mediates post-transcriptional gene silencing or mRNA target gene degradation, and is involved in the regulation of gene expression. The detection of lncRNA Sox2OT and miR-23b at the exact location and highly enriched using Ago magnetic antibody beads indicates that Sox2OT and miR-23b are in the same Ago complex. It was speculated that Sox2OT and miR-23b were in the same Ago difficult, the miR-23b level was increased, and the expression of TLR4 and NF-κb was significantly down-regulated in the silenced Sox2OT group. These results indicate that Sox2OT regulates TLR4 and mediates TLR4/NF-κb signalling pathway as a ceRNA of miR-23b. The effect of Sox2OT on miR-23b/TLR4/NF-κb may guide a novel therapeutic course for coronary embolism-induced acute heart attack. Therapeutic pathway for acute heart attacks caused by coronary embolism. More on the effect of lncRNAs on infarction lies in imaging ventricular remodelling, e.g., myocardial infarction-associated transcript 1 (Mirt1) expression correlates with the characterization of genes related to left ventricular remodelling (104); GAS5 overexpression improves new function and ventricular hypertrophy in a mouse model of myocardial infarction, all of which are of great research value.

In the study of lncRNAs mediating the development of acute myocardial infarction, many lncRNAs were found to be differentially regulated. Whether the regulatory effects of these lncRNAs, taken together, contribute to attenuating myocardial cell injury and ventricular remodelling by pyroptosis requires further validation.

6. Conclusion and prospects

Recent research on lncRNA-mediated pyroptosis has shed light on the processes behind the onset and progression of cardiovascular diseases. The suggested methods of lncRNA controlling pyroptosis by interfering with miRNA expression, in particular, have filled several major gaps in the notion of miRNA's function in cardiovascular disorders. An increasing number of biological research on the function of lncRNA-mediated pyroptosis in cardiovascular illnesses have shown that lncRNA-mediated pyroptosis will play an important role in the future screening, diagnosis, and treatment of cardiovascular disorders.

The findings of the study on lncRNA-mediated pyroptosis in the cardiovascular system have significant therapeutic implications. LncRNA GAS5, as previously noted, can enhance heart function and even cure signs of myocardial hypertrophy in DCM mice by suppressing NLRP3 activation. In diabetic cardiomyopathy patients, lncRNA can be employed as a key predictor of ventricular remodeling. In recent clinical trials, atorvastatin has been shown to reduce the occurrence of pyroptosis in patients with atherosclerosis by up-regulating the lncRNA NEXN-AS1, and the NEXN-AS1 RNA level in vascular intimal plaques in patients with atherosclerosis is also significantly lower than in healthy intimal tissues.

Although lncRNA-mediated pyroptosis are still limited to molecular biology and disease model experiments, the regulatory role of lncRNA-mediated pyroptosis in cardiovascular diseases, as well as its participation in the pathophysiological process of the cardiovascular system reflected by lncRNA, are bound to be applied and reflected in future clinical studies. The scene will be set for lncRNA-mediated pyroptosis to shine through early screening of high-risk groups for cardiovascular illnesses, as well as diagnosis and treatment of patients.

There are certain limitations in the research on the involvement of lncRNA-mediated pyroptosis in cardiovascular disorders that must be addressed. Pyroptosis is a necessary programmed death process that mediates inflammatory burst and cell death in cardiovascular diseases, and the wide range of transcript properties of lncRNAs and regulatory miRNAs is bound to shine through in the activating regulatory function of pyroptosis. The lncRNAs may be more broadly conserved across species, making determining their exact roles harder. Furthermore, translating discoveries from mice models to humans is still a considerable challenge. Because lncRNAs are more conserved at the functional and structural (secondary structure) levels than at the sequence level, lncRNA-mediated pyroptosis in cardiovascular diseases has only shown the association of lncRNAs with disease processes, with a few of these findings coming from original studies on tissue samples, but the majority still coming from bioinformatic engineering of publicly available databases such as Ensembl, GenBank, or the UCSC Genome Browser. The breadth of these discoveries is related to a wide spectrum of cardiovascular disorders, including coronary atherosclerotic heart disease, acute myocardial infarction, arrhythmias, diabetic heart disease, chronic heart failure, and congenital heart disease.

The following questions have dominated the original research on lncRNA-mediated pyroptosis control of cardiovascular disorders in the last 5 years: Is there any lncRNA-mediated focused death pathway interoperability? What signals initiate lncRNA transduction, and what controls them? What are the regulatory differences between numerous differentially expressed lncRNAs in the same disease? All of these fundamental concerns are being investigated in the context of lncRNA/miRNA/mRNA, a process that could take decades or perhaps centuries. Finally, the link between pyroptosis and other cell death procedural pathways (such as apoptosis, necroptosis, cuproptosis, and feroptosis) and their combined involvement in cell death processes in cardiovascular disorders is worth exploring in depth. We anticipate that their special networking mechanisms will have an enormous effect on clinical diagnosis and treatment efforts in the future.

Author contributions

BH and WC: participated in the information collection and and article writing. QT and YZ: participated in the later thought arrangement and language modification of the article. All authors contributed to the article and approved the submitted version.

Funding

This research was funded by the Key Research and Development Projects of Hunan Provincial Science and Technology Department (grant no. 2022SK2011, 2023TP1018); the Science and Technology Innovation Program of Hunan Province (grant no. 2021RC4064), and the Scientific Research Fund of Hunan Provincial Education Department (grant no. 22B0361).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2023.1217985/full#supplementary-material.

References

1. Liu S, Li Y, Zeng X, Wang H, Yin P, Wang L, et al. Burden of cardiovascular diseases in China, 1990–2016: findings from the 2016 global burden of disease study. JAMA Cardiol. (2019) 4(4):342–52. doi: 10.1001/jamacardio.2019.0295

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. (2009) 7(2):99–109. doi: 10.1038/nrmicro2070

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Kovacs SB, Miao EA. Gasdermins: effectors of pyroptosis. Trends Cell Biol. (2017) 27(9):673–84. doi: 10.1016/j.tcb.2017.05.005

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. (2014) 157(5):1013–22. doi: 10.1016/j.cell.2014.04.007

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Schroder K, Tschopp J. The inflammasomes. Cell. (2010) 140(6):821–32. doi: 10.1016/j.cell.2010.01.040

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. (2018) 172(3):393–407. doi: 10.1016/j.cell.2018.01.011

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Nojima T, Proudfoot NJ. Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics. Nat Rev Mol Cell Biol. (2022) 23(6):389–406. doi: 10.1038/s41580-021-00447-6

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Fasolo F, Jin H, Winski G, Chernogubova E, Pauli J, Winter H, et al. Long noncoding RNA MIAT controls advanced atherosclerotic lesion formation and plaque destabilization. Circulation. (2021) 144(19):1567–83. doi: 10.1161/CIRCULATIONAHA.120.052023

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Viereck J, Bührke A, Foinquinos A, Chatterjee S, Kleeberger JA, Xiao K, et al. Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy. Eur Heart J. (2020) 41(36):3462–74. doi: 10.1093/eurheartj/ehaa519

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Yang F, Qin Y, Lv J, Wang Y, Che H, Chen X, et al. Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy. Cell Death Dis. (2018) 9(10):1000. doi: 10.1038/s41419-018-1029-4

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Mao Q, Liang XL, Zhang CL, Pang YH, Lu YX. LncRNA KLF3-AS1 in human mesenchymal stem cell-derived exosomes ameliorates pyroptosis of cardiomyocytes and myocardial infarction through miR-138-5p/Sirt1 axis. Stem Cell Res Ther. (2019) 10(1):393. doi: 10.1186/s13287-019-1522-4

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Zhou Y, Li T, Chen Z, Huang J, Qin Z, Li L. Overexpression of lncRNA TUG1 alleviates NLRP3 inflammasome-mediated cardiomyocyte pyroptosis through targeting the miR-186-5p/XIAP axis in coronary microembolization-induced myocardial damage. Front Immunol. (2021) 12:637598. doi: 10.3389/fimmu.2021.637598

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Xuan L, Fu D, Zhen D, Bai D, Yu L, Gong G. Long non-coding RNA Sox2OT promotes coronary microembolization-induced myocardial injury by mediating pyroptosis. ESC Heart Fail. (2022) 9(3):1689–702. doi: 10.1002/ehf2.13814

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Shi HJ, Wang MW, Sun JT, Wang H, Li YF, Chen BR, et al. A novel long noncoding RNA FAF inhibits apoptosis via upregulating FGF9 through PI3K/AKT signaling pathway in ischemia-hypoxia cardiomyocytes. J Cell Physiol. (2019) 234(12):21973–87. doi: 10.1002/jcp.28760

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Xu Y, Fang H, Xu Q, Xu C, Yang L, Huang C. LncRNA GAS5 inhibits NLRP3 inflammasome activation-mediated pyroptosis in diabetic cardiomyopathy by targeting miR-34b-3p/AHR. Cell Cycle. (2020) 19(22):3054–65. doi: 10.1080/15384101.2020.1831245

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Li C, Song H, Chen C, Chen S, Zhang Q, Liu D, et al. LncRNA PVT1 knockdown ameliorates myocardial ischemia reperfusion damage via suppressing gasdermin D-mediated pyroptosis in cardiomyocytes. Front Cardiovasc Med. (2021) 8:747802. doi: 10.3389/fcvm.2021.747802

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Xiao W, Zheng D, Chen X, Yu B, Deng K, Ma J, et al. Long non-coding RNA MIAT is involved in the regulation of pyroptosis in diabetic cardiomyopathy via targeting miR-214-3p. iScience. (2021) 24(12):103518. doi: 10.1016/j.isci.2021.103518

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Meng L, Lin H, Huang X, Weng J, Peng F, Wu S. METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA. Cell Death Dis. (2022) 13(1):38. doi: 10.1038/s41419-021-04484-z

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Wang J, Zhao SM. LncRNA-antisense non-coding RNA in the INK4 locus promotes pyroptosis via miR-497/thioredoxin-interacting protein axis in diabetic nephropathy. Life Sci. (2021) 264:118728. doi: 10.1016/j.lfs.2020.118728

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Kang H, Yu H, Zeng L, Ma H, Cao G. LncRNA rian reduces cardiomyocyte pyroptosis and alleviates myocardial ischemia-reperfusion injury by regulating by the miR-17-5p/CCND1 axis. Hypertens Res. (2022) 45(6):976–89. doi: 10.1038/s41440-022-00884-6

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Zhou H, Song WH. LncRNA HCG11 accelerates atherosclerosis via regulating the miR-224-3p/JAK1 axis. Biochem Genet. (2023) 61(1):372–89. doi: 10.1007/s10528-022-10261-0

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Liu S, Xu DS, Ma JL, Huang P, Wu D, Ren LQ. LncRNA H19 mitigates oxidized low-density lipoprotein induced pyroptosis via caspase-1 in raw 264.7 cells. Inflammation. (2021) 44(6):2407–18. doi: 10.1007/s10753-021-01511-1

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Zhang P, Cao L, Zhou R, Yang X, Wu M. The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun. (2019) 10(1):1495. doi: 10.1038/s41467-019-09482-6

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem. (1986) 261(16):7123–6. doi: 10.1016/S0021-9258(17)38364-3

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Black RA, Kronheim SR, Merriam JE, March CJ, Hopp TP. A pre-aspartate-specific protease from human leukocytes that cleaves pro-interleukin-1 beta. J Biol Chem. (1989) 264(10):5323–6. doi: 10.1016/S0021-9258(18)83546-3

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. (1992) 356(6372):768–74. doi: 10.1038/356768a0

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, et al. Molecular cloning of the interleukin-1 beta converting enzyme. Science. (1992) 256(5053):97–100. doi: 10.1126/science.1373520

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Chen Y, Smith MR, Thirumalai K, Zychlinsky A. A bacterial invasin induces macrophage apoptosis by binding directly to ICE. Embo j. (1996) 15(15):3853–60. doi: 10.1002/j.1460-2075.1996.tb00759.x

PubMed Abstract | CrossRef Full Text | Google Scholar

29. D’Souza CA, Heitman J. Dismantling the cryptococcus coat. Trends Microbiol. (2001) 9(3):112–3. doi: 10.1016/S0966-842X(00)01945-4

CrossRef Full Text | Google Scholar

30. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. (2002) 10(2):417–26. doi: 10.1016/S1097-2765(02)00599-3

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. (2001) 9(3):113–4. doi: 10.1016/S0966-842X(00)01936-3

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Broz P, Pelegrín P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. (2020) 20(3):143–57. doi: 10.1038/s41577-019-0228-2

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat Commun. (2017) 8:14128. doi: 10.1038/ncomms14128

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Burdette BE, Esparza AN, Zhu H, Wang S. Gasdermin D in pyroptosis. Acta Pharm Sin B. (2021) 11(9):2768–82. doi: 10.1016/j.apsb.2021.02.006

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Rogers C, Erkes DA, Nardone A, Aplin AE, Fernandes-Alnemri T, Alnemri ES. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat Commun. (2019) 10(1):1689. doi: 10.1038/s41467-019-09397-2

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Brennan MA, Cookson BT. Salmonella induces macrophage death by caspase-1-dependent necrosis. Mol Microbiol. (2000) 38(1):31–40. doi: 10.1046/j.1365-2958.2000.02103.x

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Kuang S, Zheng J, Yang H, Li S, Duan S, Shen Y, et al. Structure insight of GSDMD reveals the basis of GSDMD autoinhibition in cell pyroptosis. Proc Natl Acad Sci U S A. (2017) 114(40):10642–7. doi: 10.1073/pnas.1708194114

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Liu Z, Wang C, Yang J, Zhou B, Yang R, Ramachandran R, et al. Crystal structures of the full-length murine and human gasdermin D reveal mechanisms of autoinhibition, lipid binding, and oligomerization. Immunity. (2019) 51(1):43–9.e4. doi: 10.1016/j.immuni.2019.04.017

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature. (2016) 535(7610):111–6. doi: 10.1038/nature18590

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. (2016) 535(7610):153–8. doi: 10.1038/nature18629

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Aglietti RA, Dueber EC. Recent insights into the molecular mechanisms underlying pyroptosis and gasdermin family functions. Trends Immunol. (2017) 38(4):261–71. doi: 10.1016/j.it.2017.01.003

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Ji N, Qi Z, Wang Y, Yang X, Yan Z, Li M, et al. Pyroptosis: a new regulating mechanism in cardiovascular disease. J Inflamm Res. (2021) 14:2647–66. doi: 10.2147/JIR.S308177

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. (2015) 265(1):6–21. doi: 10.1111/imr.12296

PubMed Abstract | CrossRef Full Text | Google Scholar

44. He WT, Wan H, Hu L, Chen P, Wang X, Huang Z, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res. (2015) 25(12):1285–98. doi: 10.1038/cr.2015.139

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev. (2011) 243(1):206–14. doi: 10.1111/j.1600-065X.2011.01044.x

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Niu T, De Rosny C, Chautard S, Rey A, Patoli D, Groslambert M, et al. NLRP3 phosphorylation in its LRR domain critically regulates inflammasome assembly. Nat Commun. (2021) 12(1):5862. doi: 10.1038/s41467-021-26142-w

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. (2009) 10(3):241–7. doi: 10.1038/ni.1703

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature. (2014) 514(7521):187–92. doi: 10.1038/nature13683

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Chu LH, Indramohan M, Ratsimandresy RA, Gangopadhyay A, Morris EP, Monack DM, et al. The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages. Nat Commun. (2018) 9(1):996. doi: 10.1038/s41467-018-03409-3

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. (2017) 42(4):245–54. doi: 10.1016/j.tibs.2016.10.004

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. (2015) 526(7575):660–5. doi: 10.1038/nature15514

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Orning P, Weng D, Starheim K, Ratner D, Best Z, Lee B, et al. Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. Science. (2018) 362(6418):1064–9. doi: 10.1126/science.aau2818

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Aachoui Y, Sagulenko V, Miao EA, Stacey KJ. Inflammasome-mediated pyroptotic and apoptotic cell death, and defense against infection. Curr Opin Microbiol. (2013) 16(3):319–26. doi: 10.1016/j.mib.2013.04.004

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Dinarello CA. Role of interleukin-1 in infectious diseases. Immunol Rev. (1992) 127:119–46. doi: 10.1111/j.1600-065X.1992.tb01411.x

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Ha HC, Snyder SH. Poly (ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A. (1999) 96(24):13978–82. doi: 10.1073/pnas.96.24.13978

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. (2000) 164(2):558–61. doi: 10.4049/jimmunol.164.2.558

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Frantz S, Ducharme A, Sawyer D, Rohde LE, Kobzik L, Fukazawa R, et al. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol. (2003) 35(6):685–94. doi: 10.1016/S0022-2828(03)00113-5

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell. (1995) 80(3):401–11. doi: 10.1016/0092-8674(95)90490-5

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Usui F, Shirasuna K, Kimura H, Tatsumi K, Kawashima A, Karasawa T, et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in western diet-fed apolipoprotein E-deficient mice. Biochem Biophys Res Commun. (2012) 425(2):162–8. doi: 10.1016/j.bbrc.2012.07.058

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Wei Y, Lan B, Zheng T, Yang L, Zhang X, Cheng L, et al. GSDME-mediated pyroptosis promotes the progression and associated inflammation of atherosclerosis. Nat Commun. (2023) 14(1):929. doi: 10.1038/s41467-023-36614-w

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, et al. The immunomodulatory metabolite itaconate modifies NLRP3 and inhibits inflammasome activation. Cell Metab. (2020) 32(3):468–78.e7. doi: 10.1016/j.cmet.2020.07.016

PubMed Abstract | CrossRef Full Text | Google Scholar

62. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. (2019) 19(8):477–89. doi: 10.1038/s41577-019-0165-0

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Gao L, Jiang Z, Han Y, Li Y, Yang X. Regulation of pyroptosis by ncRNA: a novel research direction. Front Cell Dev Biol. (2022) 10:840576. doi: 10.3389/fcell.2022.840576

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. (2021) 20(8):629–51. doi: 10.1038/s41573-021-00219-z

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, et al. Initial sequencing and comparative analysis of the mouse genome. Nature. (2002) 420(6915):520–62. doi: 10.1038/nature01262

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Lorenzen JM, Martino F, Thum T. Epigenetic modifications in cardiovascular disease. Basic Res Cardiol. (2012) 107(2):245. doi: 10.1007/s00395-012-0245-9

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Ricci Z, Romagnoli S, Ronco C. Cardiorenal syndrome. Crit Care Clin. (2021) 37(2):335–47. doi: 10.1016/j.ccc.2020.11.003

PubMed Abstract | CrossRef Full Text | Google Scholar

68. Lorenzen JM, Thum T. Long noncoding RNAs in kidney and cardiovascular diseases. Nat Rev Nephrol. (2016) 12(6):360–73. doi: 10.1038/nrneph.2016.51

PubMed Abstract | CrossRef Full Text | Google Scholar

69. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. (2011) 43(6):904–14. doi: 10.1016/j.molcel.2011.08.018

PubMed Abstract | CrossRef Full Text | Google Scholar

70. Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, Komorowski J, et al. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol Cell. (2008) 32(2):232–46. doi: 10.1016/j.molcel.2008.08.022

PubMed Abstract | CrossRef Full Text | Google Scholar

71. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. (2010) 39(6):925–38. doi: 10.1016/j.molcel.2010.08.011

PubMed Abstract | CrossRef Full Text | Google Scholar

72. Aguilo F, Zhou MM, Walsh MJ. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res. (2011) 71(16):5365–9. doi: 10.1158/0008-5472.CAN-10-4379

PubMed Abstract | CrossRef Full Text | Google Scholar

73. Murtaza G, Virk HUH, Khalid M, Lavie CJ, Ventura H, Mukherjee D, et al. Diabetic cardiomyopathy - a comprehensive updated review. Prog Cardiovasc Dis. (2019) 62(4):315–26. doi: 10.1016/j.pcad.2019.03.003

PubMed Abstract | CrossRef Full Text | Google Scholar

74. Yang F, Qin Y, Wang Y, Li A, Lv J, Sun X, et al. LncRNA KCNQ1OT1 mediates pyroptosis in diabetic cardiomyopathy. Cell Physiol Biochem. (2018) 50(4):1230–44. doi: 10.1159/000494576

PubMed Abstract | CrossRef Full Text | Google Scholar

75. Jin X, Jin H, Shi Y, Guo Y, Zhang H. Long non-coding RNA KCNQ1OT1 promotes cataractogenesis via miR-214 and activation of the caspase-1 pathway. Cell Physiol Biochem. (2017) 42(1):295–305. doi: 10.1159/000477330

PubMed Abstract | CrossRef Full Text | Google Scholar

76. Jiang Y, Du W, Chu Q, Qin Y, Tuguzbaeva G, Wang H, et al. Downregulation of long non-coding RNA Kcnq1ot1: an important mechanism of arsenic trioxide-induced long QT syndrome. Cell Physiol Biochem. (2018) 45(1):192–202. doi: 10.1159/000486357

PubMed Abstract | CrossRef Full Text | Google Scholar

77. Chen D, Zhang M. GAS5 regulates diabetic cardiomyopathy via miR-221-3p/p27 axis-associated autophagy. Mol Med Rep. (2021) 23(2):135. doi: 10.3892/mmr.2020.11774

PubMed Abstract | CrossRef Full Text | Google Scholar

78. Zhu C, Zhang H, Wei D, Sun Z. Silencing lncRNA GAS5 alleviates apoptosis and fibrosis in diabetic cardiomyopathy by targeting miR-26a/b-5p. Acta Diabetol. (2021) 58(11):1491–501. doi: 10.1007/s00592-021-01745-3

PubMed Abstract | CrossRef Full Text | Google Scholar

79. Chu PM, Yu CC, Tsai KL, Hsieh PL. Regulation of oxidative stress by long non-coding RNAs in vascular complications of diabetes. Life. (2022) 12(2):274. doi: 10.3390/life12020274

CrossRef Full Text | Google Scholar

80. Wang C, Liu G, Yang H, Guo S, Wang H, Dong Z, et al. MALAT1-mediated recruitment of the histone methyltransferase EZH2 to the microRNA-22 promoter leads to cardiomyocyte apoptosis in diabetic cardiomyopathy. Sci Total Environ. (2021) 766:142191. doi: 10.1016/j.scitotenv.2020.142191

PubMed Abstract | CrossRef Full Text | Google Scholar

81. Abo-Saif MA, Ragab AE, Ibrahim AO, Abdelzaher OF, Mehanyd ABM, Saber-Ayad M, et al. Pomegranate peel extract protects against the development of diabetic cardiomyopathy in rats by inhibiting pyroptosis and downregulating LncRNA-MALAT1. Front Pharmacol. (2023) 14:1166653. doi: 10.3389/fphar.2023.1166653

PubMed Abstract | CrossRef Full Text | Google Scholar

82. Abdulle LE, Hao JL, Pant OP, Liu XF, Zhou DD, Gao Y, et al. MALAT1 as a diagnostic and therapeutic target in diabetes-related complications: a promising long-noncoding RNA. Int J Med Sci. (2019) 16(4):548–55. doi: 10.7150/ijms.30097

PubMed Abstract | CrossRef Full Text | Google Scholar

83. Che H, Wang Y, Li H, Li Y, Sahil A, Lv J, et al. Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/smads signaling in diabetic cardiomyopathy. Faseb J. (2020) 34(4):5282–98. doi: 10.1096/fj.201902692R

PubMed Abstract | CrossRef Full Text | Google Scholar

84. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. (2019) 5(1):56. doi: 10.1038/s41572-019-0106-z

PubMed Abstract | CrossRef Full Text | Google Scholar

85. Fidler TP, Xue C, Yalcinkaya M, Hardaway B, Abramowicz S, Xiao T, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. (2021) 592(7853):296–301. doi: 10.1038/s41586-021-03341-5

PubMed Abstract | CrossRef Full Text | Google Scholar

86. Xu YJ, Zheng L, Hu YW, Wang Q. Pyroptosis and its relationship to atherosclerosis. Clin Chim Acta. (2018) 476:28–37. doi: 10.1016/j.cca.2017.11.005

PubMed Abstract | CrossRef Full Text | Google Scholar

87. Hu YW, Guo FX, Xu YJ, Li P, Lu ZF, McVey DG, et al. Long noncoding RNA NEXN-AS1 mitigates atherosclerosis by regulating the actin-binding protein NEXN. J Clin Invest. (2019) 129(3):1115–28. doi: 10.1172/JCI98230

PubMed Abstract | CrossRef Full Text | Google Scholar

88. Wu LM, Wu SG, Chen F, Wu Q, Wu CM, Kang CM, et al. Atorvastatin inhibits pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human vascular endothelial cells. Atherosclerosis. (2020) 293:26–34. doi: 10.1016/j.atherosclerosis.2019.11.033

PubMed Abstract | CrossRef Full Text | Google Scholar

89. Josefs T, Boon RA. The long non-coding road to atherosclerosis. Curr Atheroscler Rep. (2020) 22(10):55. doi: 10.1007/s11883-020-00872-6

PubMed Abstract | CrossRef Full Text | Google Scholar

90. Sharma BR, Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol. (2021) 22(5):550–9. doi: 10.1038/s41590-021-00886-5

PubMed Abstract | CrossRef Full Text | Google Scholar

91. Gu P, Hui X, Zheng Q, Gao Y, Jin L, Jiang W, et al. Mitochondrial uncoupling protein 1 antagonizes atherosclerosis by blocking NLRP3 inflammasome-dependent interleukin-1β production. Sci Adv. (2021) 7(50):eabl4024. doi: 10.1126/sciadv.abl4024

PubMed Abstract | CrossRef Full Text | Google Scholar

92. Duan Y, Zhang L, Angosto-Bazarra D, Pelegrín P, Núñez G, He Y. RACK1 mediates NLRP3 inflammasome activation by promoting NLRP3 active conformation and inflammasome assembly. Cell Rep. (2020) 33(7):108405. doi: 10.1016/j.celrep.2020.108405

PubMed Abstract | CrossRef Full Text | Google Scholar

93. Schunk SJ, Kleber ME, März W, Pang S, Zewinger S, Triem S, et al. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur Heart J. (2021) 42(18):1742–56. doi: 10.1093/eurheartj/ehab107

PubMed Abstract | CrossRef Full Text | Google Scholar

94. Cremer S, Michalik KM, Fischer A, Pfisterer L, Jaé N, Winter C, et al. Hematopoietic deficiency of the long noncoding RNA MALAT1 promotes atherosclerosis and plaque inflammation. Circulation. (2019) 139(10):1320–34. doi: 10.1161/CIRCULATIONAHA.117.029015

PubMed Abstract | CrossRef Full Text | Google Scholar

95. Fasolo F, Di Gregoli K, Maegdefessel L, Johnson JL. Non-coding RNAs in cardiovascular cell biology and atherosclerosis. Cardiovasc Res. (2019) 115(12):1732–56. doi: 10.1093/cvr/cvz203

PubMed Abstract | CrossRef Full Text | Google Scholar

96. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. (2014) 11(5):255–65. doi: 10.1038/nrcardio.2014.28

PubMed Abstract | CrossRef Full Text | Google Scholar

97. Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, et al. ST-segment elevation myocardial infarction. Nat Rev Dis Primers. (2019) 5(1):39. doi: 10.1038/s41572-019-0090-3

PubMed Abstract | CrossRef Full Text | Google Scholar

98. Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. (2020) 17(12):773–89. doi: 10.1038/s41569-020-0403-y

PubMed Abstract | CrossRef Full Text | Google Scholar

99. Lee S, Choi E, Cha MJ, Hwang KC. Looking for pyroptosis-modulating miRNAs as a therapeutic target for improving myocardium survival. Mediators Inflamm. (2015) 2015:254871. doi: 10.1155/2015/254871

PubMed Abstract | CrossRef Full Text | Google Scholar

100. Gezer U, Özgür E, Cetinkaya M, Isin M, Dalay N. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes. Cell Biol Int. (2014) 38(9):1076–9. doi: 10.1002/cbin.10301

PubMed Abstract | CrossRef Full Text | Google Scholar

101. Gu J, Shi JZ, Wang YX, Liu L, Wang SB, Sun JT, et al. LncRNA FAF attenuates hypoxia/ischaemia-induced pyroptosis via the miR-185-5p/PAK2 axis in cardiomyocytes. J Cell Mol Med. (2022) 26(10):2895–907. doi: 10.1111/jcmm.17304

PubMed Abstract | CrossRef Full Text | Google Scholar

102. Li CC, Qiu XT, Sun Q, Zhou JP, Yang HJ, Wu WZ, et al. Endogenous reduction of miR-185 accelerates cardiac function recovery in mice following myocardial infarction via targeting of cathepsin K. J Cell Mol Med. (2019) 23(2):1164–73. doi: 10.1111/jcmm.14016

PubMed Abstract | CrossRef Full Text | Google Scholar

103. Shahryari A, Jazi MS, Samaei NM, Mowla SJ. Long non-coding RNA SOX2OT: expression signature, splicing patterns, and emerging roles in pluripotency and tumorigenesis. Front Genet. (2015) 6:196. doi: 10.3389/fgene.2015.00196

PubMed Abstract | CrossRef Full Text | Google Scholar

104. Wang X, Li Z, Du Y, Xing Y, Guo Y, Zhang Y, et al. lncRNA Mirt1: a critical regulatory factor in chronic intermittent hypoxia exaggerated post-MI cardiac remodeling. Front Genet. (2022) 13:818823. doi: 10.3389/fgene.2022.818823

PubMed Abstract | CrossRef Full Text | Google Scholar